<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646735</url>
  </required_header>
  <id_info>
    <org_study_id>10982</org_study_id>
    <nct_id>NCT02646735</nct_id>
  </id_info>
  <brief_title>Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients</brief_title>
  <acronym>FRIEND</acronym>
  <official_title>A Randomized, Open Label, Multi-Centre Study to Compare the Efficacy and Tolerability of Fulvestrant 500mg With Exemestane for Postmenopausal Advanced Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be
      randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy and tolerability of Fulvestrant 500 mg with Exemestane 25 mg as first
      line endocrine therapy in postmenopausal women with oestrogen receptor positive HER2 negative
      advanced breast cancer who have relapsed on or after adjuvant non-aromatase inhibitor therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>To compare the efficacy of Fulvestrant 500 mg with the patients treated with Exemestane 25mg as first line setting in terms of progression-free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 years</time_frame>
    <description>To compare the objective response rate of patients treated with Fulvestrant 500 mg with Exemestane.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exemestane 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant 500 mg</intervention_name>
    <description>Fulvestrant 500mg will be given monthly.</description>
    <arm_group_label>Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane 25 mg</intervention_name>
    <description>Exemestane 25mg will be given once daily.</description>
    <arm_group_label>Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent document on file;

          -  Age over 60 years;

          -  Age &lt; 60 years and amenorrheic for 12 or more months in the absence of chemotherapy,
             tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol level in the
             postmenopausal range;

          -  Patients with metastatic or locally advanced disease not amenable to therapy with
             Curative intent

          -  ER + and/or PgR +;

          -  Duration of adjuvant non-aromatase inhibitors treatment should be at least 2 years or
             more;

          -  WHO performance status 0, 1 or 2;

          -  Patients with life expectancy of more than 3 months.

        Exclusion Criteria:

          -  Presence of life-threatening metastatic visceral disease;

          -  Previous systemic chemotherapy for advanced breast cancer;

          -  Received systemic endocrine therapy for advanced disease;

          -  Extensive radiation therapy within the last 4 weeks ;

          -  Platelets &lt; 100*109 / L,Total bilirubin no less than 1.5ULRR, ALT or AST no less than
             2.5ULRR if no demonstrable liver metastases or no less than 5ULRR in presence of liver
             metastases;

          -  Severe renal impairment, bleeding diathesis, long-term anticoagulant therapy;

          -  History of hypersensitivity to active or inactive excipients of fulvestrant,
             Exemestane and/or castor oil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XU Binghe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>XU Binghe, MD</last_name>
    <phone>86-10-87788495</phone>
    <phone_ext>0000</phone_ext>
    <email>wangjiayu8778@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>WANG Jiayu, MD</last_name>
    <phone>86-10-87788495</phone>
    <phone_ext>0000</phone_ext>
    <email>wangjiayu8778@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe XU, M.D.</last_name>
      <phone>86-10-88788826</phone>
      <email>xubinghe@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jiayu WANG, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Head of the medical department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

